Children with ADHD (attention deficit hyperactivity disorder) show signs of improvement after playing a video game for 30 minutes a day rather than taking a pill, the US company developing the treatment said on Wednesday.

Diagnoses of ADHD have risen in recent decades, and some 9.5 per cent of children aged 3-17 in the US had the condition in 2012, according to the Centre for Disease Control and Prevention.

Children in the pilot study – 80 aged between eight and 12, half of whom had ADHD – showed improved working memory and levels of attention, and some parent ratings of symptoms also rose, according to the results presented at the American Academy of Child and Adolescent Psychiatry’s 62nd annual meeting.

Diagnoses of ADHD have risen in recent decades,and some 9.5 per cent of children aged 3-17 in the US had the condition in 2012

The company, Akili Interactive Labs, said it would now “move full steam ahead” into a full randomised trial, that if successful would support a filing with US regulator, the FDA. Medicating the condition is big business, with Shire – a leading maker of ADHD drugs, including Vyvanse – saying there were 63 million prescriptions for the condition in the US last year, with just under half for children.

Shire is an investor in Akili Interactive Labs, which was founded by start-up investor PureTech Health.

Eddie Martucci, co-founder and chief executive of Akili Interactive Labs, said the video game might also be used in conjuction with medication.

Called Project EVO, the game is designed to improve a child’s ability to process “cognitive interference”– or multiple streams of information – potentially helping problem-solving ability, working memory and attention, Martucci said.

The player has to steer a character down a river while making decisions about objects that appear on screen.

Sign up to our free newsletters

Get the best updates straight to your inbox:
Please select at least one mailing list.

You can unsubscribe at any time by clicking the link in the footer of our emails. We use Mailchimp as our marketing platform. By subscribing, you acknowledge that your information will be transferred to Mailchimp for processing.